# A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

> **NCT06292013** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 17300 (estimated)

## Conditions studied

- Atherosclerotic Cardiovascular Disease (ASCVD)
- Elevated Lp(a)

## Interventions

- **DRUG:** Lepodisiran Sodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06292013
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-05
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 17300 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06292013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06292013, "A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT06292013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*